» Articles » PMID: 35352018

Pan-KRAS Inhibitors Suppress Proliferation Through Feedback Regulation in Pancreatic Ductal Adenocarcinoma

Overview
Specialty Pharmacology
Date 2022 Mar 30
PMID 35352018
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is currently one of the most lethal cancers worldwide. Several basic studies have confirmed that Kirsten rat sarcoma virus (KRAS) is a key driver gene for the occurrence of PDAC, and KRAS mutations have also been found in most patients in clinical studies. In this study, two pan-KRAS inhibitors, BI-2852 and BAY-293, were chosen as chemical probes to investigate their antitumor potency in PDAC. Their inhibitory effects on KRAS activation were validated in vitro and their antiproliferative potency in PDAC cell lines were profiled, with half-maximal inhibitory concentration (IC) values of approximately 1 μM, demonstrating the therapeutic potential of pan-KRAS inhibitors in the treatment of PDAC. However, feedback regulation in the KRAS pathway weakened inhibitor activity, which was observed by a 50 times difference in BAY-293 from in vitro activity. Furthermore, pan-KRAS inhibitors effectively inhibited cell proliferation in 3D organoids cultured from PDAC patient samples; however, there were some variations between individuals. These results provide a sufficient theoretical foundation for KRAS as a clinical therapeutic target and for the application of pan-KRAS inhibitors in the treatment of PDAC, with important scientific significance in translational medicine.

Citing Articles

Recent Anti-KRAS Therapies: A "Possible Impossibility" for Pancreatic Ductal Adenocarcinoma.

Sobhani N, Pittacolo M, DAngelo A, Marchegiani G Cancers (Basel). 2025; 17(4).

PMID: 40002297 PMC: 11853620. DOI: 10.3390/cancers17040704.


Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare mutations: a real-world retrospective study.

Jiang H, Li Y, Wang Y, Zou B, Chen Y, Zhang Y Transl Lung Cancer Res. 2024; 13(7):1672-1684.

PMID: 39118889 PMC: 11304142. DOI: 10.21037/tlcr-24-372.


Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.

Klomp J, Klomp J, Stalnecker C, Bryant K, Edwards A, Drizyte-Miller K Science. 2024; 384(6700):eadk0775.

PMID: 38843331 PMC: 11301402. DOI: 10.1126/science.adk0775.


Targeting the 'Undruggable' Driver Protein, KRAS, in Epithelial Cancers: Current Perspective.

Lam K, Wong S, Cheah P Cells. 2023; 12(4).

PMID: 36831298 PMC: 9954350. DOI: 10.3390/cells12040631.


Computer-Aided Drug Design Boosts RAS Inhibitor Discovery.

Wang G, Bai Y, Cui J, Zong Z, Gao Y, Zheng Z Molecules. 2022; 27(17).

PMID: 36080477 PMC: 9457765. DOI: 10.3390/molecules27175710.


References
1.
Iodice S, Gandini S, Maisonneuve P, Lowenfels A . Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008; 393(4):535-45. DOI: 10.1007/s00423-007-0266-2. View

2.
Vetter I, Wittinghofer A . The guanine nucleotide-binding switch in three dimensions. Science. 2001; 294(5545):1299-304. DOI: 10.1126/science.1062023. View

3.
Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C . Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018; 37(1):57. PMC: 5850913. DOI: 10.1186/s13046-018-0719-1. View

4.
Howes J, Akan D, Burns M, Rossanese O, Waterson A, Fesik S . Small Molecule-Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1. Mol Cancer Ther. 2018; 17(5):1051-1060. DOI: 10.1158/1535-7163.MCT-17-0666. View

5.
Li X, Wang C, Peng T, Chai Z, Ni D, Liu Y . Atomic-scale insights into allosteric inhibition and evolutional rescue mechanism of Cas9 by the anti-CRISPR protein AcrIIA6. Comput Struct Biotechnol J. 2021; 19:6108-6124. PMC: 8632846. DOI: 10.1016/j.csbj.2021.11.010. View